Amneal Pharmaceuticals, Inc.
AMRX
$6.98
$0.010.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.73% | 12.32% | 12.37% | 9.82% | 8.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.73% | 12.32% | 12.37% | 9.82% | 8.20% |
| Cost of Revenue | 16.26% | 11.30% | 10.90% | 7.83% | 7.67% |
| Gross Profit | 17.55% | 14.14% | 15.07% | 13.43% | 9.15% |
| SG&A Expenses | 10.88% | 8.02% | 10.04% | 9.19% | 7.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 100.00% | 101.83% | 101.66% | 71.26% |
| Total Operating Expenses | 15.24% | 11.00% | 9.77% | 6.85% | 5.47% |
| Operating Income | 28.37% | 22.33% | 34.30% | 36.73% | 35.65% |
| Income Before Tax | -36.61% | -446.56% | -883.39% | 57.05% | 83.77% |
| Income Tax Expenses | 123.18% | 822.52% | 414.37% | 29.18% | 26.87% |
| Earnings from Continuing Operations | -51.63% | -477.87% | -1,274.52% | 53.45% | 80.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -21.94% | -33.53% | -209.31% | -139.13% | -128.26% |
| Net Income | -39.16% | -1,886.83% | -8,426.17% | -25.17% | 35.38% |
| EBIT | 28.37% | 22.33% | 34.30% | 36.73% | 35.65% |
| EBITDA | 16.73% | 10.85% | 14.78% | 14.83% | 13.75% |
| EPS Basic | -22.41% | -1,134.95% | -4,181.38% | 36.92% | 63.98% |
| Normalized Basic EPS | -291.08% | -92.31% | -87.53% | -99.11% | -96.27% |
| EPS Diluted | -20.20% | -1,311.84% | -2,572.65% | 37.04% | 63.33% |
| Normalized Diluted EPS | -290.58% | -92.31% | -87.53% | -99.10% | -96.26% |
| Average Basic Shares Outstanding | 75.61% | 91.28% | 66.63% | 41.75% | 16.57% |
| Average Diluted Shares Outstanding | 75.36% | 90.82% | 68.83% | 42.84% | 17.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
